MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1498-1502

  Bhan, Sheetal ^a   Chuang, Alice ^a   Negi, Sandeep S ^a   Glazer, Chad A ^a   Califano, Joseph A ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Cancer testis antigens; Head and neck squamous cell carcinoma; MAGEA4

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MELANOMA ANTIGEN 4; PROTEIN BAX;

APOPTOSIS; ARTICLE; BAX GENE; CDKN1A GENE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; GENE; GENE REPRESSION; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; KERATINOCYTES; MOUTH; NEOPLASM PROTEINS;

EID: 84866454696     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1934     Document Type: Article

References (26)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625, 2005.
2. Zendman AJ, Ruiter DJ and Van Muijen GN: Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 194: 272-288, 2003.
3. Koslowski M, Bell C, Seitz G, et al: Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res 64: 5988-5993, 2004.
4. Caballero OL and Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100: 2014-2021, 2009.
5. Barker PA and Salehi A: The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67: 705-712, 2002.
6. Sugita M, Geraci M, Gao B, et al: Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62: 3971-3979, 2002.
7. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F and Boon T: The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93: 7149-7153, 1996.
8. De Smet C, Lurquin C, Lethe B, Martelange V and Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19: 7327-7335, 1999.
9. Weber J, Salgaller M, Samid D, et al: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza- 2′- deoxycytidine. Cancer Res 54: 1766-1771, 1994.
10. Glazer CA, Smith IM, Ochs MF, et al: Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PloS One 4: e8189, 2009.
11. Smith IM, Glazer CA, Mithani SK, et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PloS One 4: e4961, 2009.
12. Bhan S, Negi SS, Shao C, et al: BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res 17: 4267-4276, 2011.
13. Vatolin S, Abdullaev Z, Pack SD, et al: Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65: 7751-7762, 2005.
14. Hong JA, Kang Y, Abdullaev Z, et al: Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65: 7763-7774, 2005.
15. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32, 2002.
16. Ghafouri-Fard S and Modarressi MH: Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med 12: 395-404, 2009.
17. Morishima N, Nakanishi K, Takenouchi H, Shibata T and Yasuhiko Y: An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 277: 34287-34294, 2002.
18. Monte M, Simonatto M, Peche LY, et al: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103: 11160-11165, 2006.
19. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M and Longley BJ: Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127: 267-275, 2007.
20. Yang B, O'Herrin SM, Wu J, et al: MAGE-A, mMage-B, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67: 9954-9962, 2007.
21. Glazer CA, Smith IM, Bhan S, et al: The role of MAGEA2 in head and neck cancer. Arch Otolaryngol Head Neck Surg 137: 286-293, 2011.
22. Peikert T, Specks U, Farver C, Erzurum SC and Comhair SA: Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 66: 4693-4700, 2006.
23. Nagao T, Higashitsuji H, Nonoguchi K, et al: MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278: 10668-10674, 2003.
24. Jin QH, Zhao B and Zhang XJ: Cytochrome c release and endoplasmic reticulum stress are involved in caspase-dependent apoptosis induced by G418. Cell Mol Life Sci 61: 1816-1825, 2004.
25. Kuribayashi K and El Deiry WS: Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 615: 201-221, 2008.
26. Lincet H, Poulain L, Remy JS, Deslandes E, Duigou F, Gauduchon P and Staedel C: The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 161: 17-26, 2000.